I N T E R V I E W
collaborations , the plasma nutrition project stands out for its rapid progress ; we ' ve already initiated smallscale production and distribution to key protein distributors . Anticipating a substantial uptick in commercial volume within the next 6 to 9 months , we ' re confident that ioProtein ' s unparalleled advantages will position ' IO ' technology as the go-to for healthconscious individuals , reshaping the nutrition industry along the way .
Innovation is crucial in any industry . How much does the company spend annually on R & D ? Tell us about the key R & D centre , team and focus of research ?
The company always focuses on deepening its knowledge based across complex chemistries , technologies , and patented processes . Our R & D lab at Lote Parshuram is now commissioned and in operation and our pilot plant at Ambernath Lab , will be operational by Q4 FY ‘ 24 . These centres will be used for the next phase of expansion for rolling out our new APIs and CMO and CDMO business . With these projects the total capacity will increase from 597 KL to 900 KL . Currently we are doing business with over 1200 + customers and have a presence in more than 86 countries . We have taken additional steps for business expansion around the globe especially in regulated markets like the North America market , Japan , Australia , and New Zealand . We have recently announced one of our key CMO
projects with a leading European company where we will be exclusive API supplier . The contract spans a period of 10 years and is expected to generate peak revenue of Rs 40 crore per year starting from FY27 .
How do you plan to expand your global reach and product portfolio ? Any key announcements in the offing ?
Company has taken additional steps for business expansion around the globe especially in the North America market , Japan , Australia , and New Zealand . The company expects an uptake in volumes from FY25 due to the CDMO deals which will significantly contribute to the revenue . Going forward the company will be focusing on Europe , North America , and Latin America to drive growth . The management is confident about achieving a minimum of 20-25 % growth in the topline . The company has 6 molecules in the pipeline which are to be registered in China . The company committed to build a pipeline of new products , which could extend it beyond its longstanding competence in the area of antihistamines and towards antidiabetics and other areas .
Sustainability and environmental concerns are increasingly important . How is the company incorporating sustainability practices and considerations into its operations and offerings ?
Supriya Lifescience has fortified its strengths by adopting an
56
BioVoiceNews | January / February 2024